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successfully but only after introducing a multiplicative scale parameter to distin-
guish between both approaches. With 1600 respondents, adding 1 TTO offers more
informative value than adding 1 DC but not as much as adding 2 DC’s.
CONCLUSIONS:The likelihood approach effectively estimates the structure under-
lying the simulated data. Given that DC is less burdensome than TTO, one may
prefer to add more DC’s than TTO’s. That is – as in this case – when the underlying
modelling assumption apply.
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OBJECTIVES: In 2002, PROQOLID was launched to provide an overview of existing
PRO instruments and facilitate access to the instruments and their developers,
through the structured presentation of synthesized, reliable, and updated data. In
2009, the Food and Drug administration (FDA) published its final guidance on the
use of PRO measures which describes how the FDA will review PRO instruments
used to support claims in approved medical product labeling. The objectives of this
study were to review and adapt the template of PROQOLID to harmonize its struc-
ture and language with those used in the FDA guidance, acknowledging that PRO-
QOLID and the guidance have different OBJECTIVES: provision of information vs.
review of information.METHODS:Content and structure of PROQOLID and the FDA
guidance were compared. Proposed changes in terminology and structure were
submitted to a panel of PRO experts (n2). RESULTS: The information on PRO-
QOLID is divided into 12 sections. The FDA guidance categorizes information into 5
parts. Twelve changes in terminology were made across all sections. For instance,
Time recall” was changed to “Recall/Observation period”, and “Dimensions” to “Do-
mains”. Fourteen changes of structure were made, mainly in Sections 6 and 7. Section
6 (Methodology of development) was renamed “Content Validity documentation”. In
this section, the heading “Information retrieval” was replaced by “Concept elicitation
and Item generation”. “Conceptual framework” will be moved to Section 5 (Descriptive
information). Section 7 (Psychometric properties) was renamed “Measurement Prop-
erties”. Within the “Reliability” heading, a subheading on “Inter-interviewer reproduc-
ibility” was added. A new section was created: “Data analysis and Interpretation. Five
sections remained unchanged (1 to 4, and 8). CONCLUSIONS: The comparison of
PROQOLID and the FDA guidance led to numerous changes in the wording and
structure of the database. These changes will improve the functionality of PRO-
QOLID and help users to better fulfill FDA requirements.
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OBJECTIVES: To assess the validity and responsiveness of the SF-36, SF-12, SF-6D
and EQ-5D in mental health conditions. METHODS: Systematic reviews were un-
dertaken in five mental health conditions. Ten databases were searched to August
2009. Studies were appraised and data extracted. A narrative synthesis was per-
formed on construct validity including known groups validity (KGV) (ability to de-
tect differences in HRQL scores between groups), convergent validity (CV) (strength
of association between generic HRQL and other related measures (e.g. symptoms or
function) and responsiveness (R) (i.e. changes in scores in responders/non-re-
sponders to treatment and correlation with changes in related measures).
RESULTS: Within schizophrenia, the majority of evidence related to the SF-36
(n25) and EQ-5D (n9). Both measures demonstrated KGV but this was mostly
limited to demonstrating differences between individuals with schizophrenia and
the general population. Contradictory results were found in studies measuring CV
and R using clinical measures of symptom severity. For bipolar disorder, 23 studies
were identified, almost exclusively on the SF-36; which was able to detect known
differences in symptom severity and correlated strongly with clinical measures of
depression (weakly with mania measures). For personality disorders; the majority
of studies (6/9) related to the EQ-5D, which showed good KGV and R. For depression
and anxiety, 23 EQ-5D and eight SF-6D studies were identified. Both measures
demonstrated good CV and R for depression; however KGV may be driven by the
presence of co-morbid depression in patients with anxiety disorders.
CONCLUSIONS: Overall, the evidence suggests that the generic HRQL measures are
appropriate in four mental health conditions, but raises doubts about their use in
schizophrenia. Caution is required when interpreting CV evidence using clinical mea-
sures, since the lack of relationship may reflect genuine lack of difference in HRQL. More
evidence using better indicators for testing validity and responsiveness are required.
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OBJECTIVES: To compare EQ-5D and SF-6D utilities in patients with chronic pain
due to osteoarthritis (OA) of the knee or low back pain (LBP) derived from phase III
trials with tapentadol. METHODS: Three phase III trials with identical design in-
cluded EQ-5D and SF-36 questionnaires to measure quality of life of patients with
pain due to OA or LBP treated with tapentadol prolonged release (PR), oxycodone
controlled release (CR) or placebo. EQ-5D and SF-6D indices were obtained using
the UK weights. The ability of the two utility measurements to discriminate among
different health states was tested. RESULTS: Both SF-6D and EQ-5D utility values
increased from baseline to endpoint (15 weeks). The increase (mean of all patients
with active treatment) was substantially higher when measured with EQ-5D (0.16
vs. 0.06). The EQ-5D better distinguished among health states (different severity of
adverse events, pain relief, withdrawal rates). While utilities were very similar in a
group of patients who tolerated the treatment (0.695 and 0.694 for EQ-5D and SF-6D,
respectively), EQ-5D utilities were considerably lower in patients who withdrew
due to adverse events (0.503 and 0.597 for EQ-5D and SF-6D, respectively). A similar
pattern was seen in patients with various levels of pain relief. In patients with
30% pain relief mean EQ-5D and SF-6D utility was 0.716 and 0.708, respectively.
The EQ-5D utility in patients who withdrew due to lack of efficacy was 0.405, when
analyzing the SF-6D utility this resulted in 0.580. CONCLUSIONS: Both generic
instruments to measure quality of life, EQ-5D and SF-6D, showed that avoidance of
severe treatment-related adverse events and sufficient pain relief has a large ben-
eficial impact on patient’s wellbeing. In the clinical trials analyzed the discrimina-
tive power of the EQ-5D was stronger showing that this instrument is a useful tool
also in pain studies to analyze patient’s QoL.
PODIUM SESSION II:
DISCUSSIONS ON THE ADDED VALUE OF VALUE OF INFORMATION
VI1
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The conditional reimbursement policy for expensive medicines in the The Nether-
lands requires real-world data collection on cost-effectiveness within a four years
period (T4) after the initial decision to reimburse a drug (T0). This introduces
new sources of uncertainty, which are less important in an RCT than in real life. This
may affect the priorities for further (real-world) research as determined in a VOI
analysis. OBJECTIVES: Identifying and modeling types of uncertainty that are usu-
ally not parameterized at T0 but may become relevant at T4. Include them in the
VOI analysis.METHODS:We use a hypothetical model with four states and param-
eters related to transition and exacerbation probabilities, costs and utilities. Three
additional uncertainties were parameterized: persistence, compliance and broad-
ening of indication. Persistence refers to the duration of the treatment and it is
determined by the probability of dropping out of the treatment. Compliance is
characterized by the fraction of the treatment benefit obtained due to not taking
the medication as it was indicated. The impact of indication broadening is modeled
as the percentage of the RCT treatment effect realized in the outcome study. These
extra parameters were included in the VOI analysis. RESULTS: Priorities change
when new uncertainties are introduced in the model. Initially, the EVPPI was high-
est for transition probabilities followed by utilities; and it was very low for exacer-
bation probabilities and costs. After new uncertainties are included, compliance
and broadening of indication (which is applied only to the new treatment) become
as relevant as utilities. Persistence however has little impact in the model.
CONCLUSIONS:VOI analysis at T0 should anticipate and parameterize new types
of uncertainty that may emerge during a four year outcomes study. This would
help to focus the real-world outcomes study on those parameters that reduce
uncertainty in the decision to continue the reimbursement most.
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OBJECTIVES: To develop a novel semi-quantitative model to assist pharmaceutical
companies in making investment decisions, by assessing relative importance of
value drivers in a given therapy area and how this translates to perceived value of
a product profile. METHODS: Perceived value for a number of product profiles is
assessed through a semi-quantitative scoring method, followed by an in-depth
qualitative interview. In the scoring phase, respondents rate the relative impor-
tance of value drivers and provide thresholds for minimal and strong value in each
domain. Respondents assess target product profiles, scoring profile performance in
each value driver on a pre-defined scale. RESULTS: This methodology provides a
range of valuable data in understanding the drivers of value in a given therapy area.
First, the relative importance of value drivers can be used to understand which
product attributes (efficacy, safety and tolerability or administration and others)
drive product value. In addition, by providing value thresholds for each driver, we
can understand expectations, in effect defining an ‘ideal’ product scenario. Testing
product profiles against a scale calibrated by these expectations allows us to un-
derstand perceived product value in a set of likely product attributes. In addition,
by testing a number of profiles, trade-offs between different product attributes, and
the effect of these on product value, can be assessed. CONCLUSIONS: The insights
gained from this type of analysis are vital in understanding product development
priorities and the likely pricing and reimbursement potential for future products.
Multiple applications of this technique have confirmed that this is a valuable ap-
proach in supporting pharmaceutical companies to inform their clinical pro-
gramme, pricing and reimbursement strategy or commercial strategy.
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SEQUENTIAL TREATMENT OF FOLLICULAR NON-HODGKIN LYMPHOMA: COST-
EFFECTIVENESS AND VALUE OF INFORMATION
Soini EJ1, Martikainen JA1, Vihervaara V2, Mustonen K2, Nousiainen T3
1ESiOR Ltd, Kuopio, Finland, 2Roche Oy, Espoo, Finland, 3Department of Medicine, University of
Eastern Finland and Kuopio University Hospital, Kuopio, Finland
A239V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
